Bank of New York Mellon Corp Sells 41,579 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Bank of New York Mellon Corp cut its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,527,586 shares of the pharmaceutical company’s stock after selling 41,579 shares during the quarter. Bank of New York Mellon Corp’s holdings in Vertex Pharmaceuticals were worth $692,546,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of VRTX. Colonial Trust Co SC increased its position in shares of Vertex Pharmaceuticals by 118.8% during the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 38 shares during the last quarter. Eagle Bay Advisors LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $29,000. IMG Wealth Management Inc. increased its position in shares of Vertex Pharmaceuticals by 277.8% during the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 50 shares during the last quarter. Ares Financial Consulting LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $33,000. Finally, Archer Investment Corp increased its position in shares of Vertex Pharmaceuticals by 89.7% during the 4th quarter. Archer Investment Corp now owns 74 shares of the pharmaceutical company’s stock valued at $34,000 after purchasing an additional 35 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

VRTX has been the topic of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $590.00 price objective on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Royal Bank Of Canada increased their price objective on Vertex Pharmaceuticals from $541.00 to $543.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Oppenheimer increased their target price on Vertex Pharmaceuticals from $540.00 to $600.00 and gave the company an “outperform” rating in a report on Tuesday, March 10th. Bank of America increased their target price on Vertex Pharmaceuticals from $571.00 to $598.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Finally, Wall Street Zen cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 30th. Twenty-two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $555.91.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $428.34 on Thursday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $507.92. The stock has a 50 day simple moving average of $437.63 and a two-hundred day simple moving average of $451.81. The stock has a market cap of $108.71 billion, a P/E ratio of 25.41, a price-to-earnings-growth ratio of 1.82 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.23. The business had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The business’s revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the business posted $4.06 EPS. Sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 16.99 earnings per share for the current year.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: The FDA accepted Vertex’s Biologics License Application for povetacicept in adults with IgA nephropathy, putting the company one step closer to a potential new nephrology launch and a regulatory decision expected on November 30, 2026. This is an important pipeline milestone that could expand Vertex’s growth story beyond cystic fibrosis. FDA Accepts Vertex’s BLA for Povetacicept in IgA Nephropathy
• Positive Sentiment: Vertex will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, with CEO Reshma Kewalramani scheduled for a fireside chat. Investors may view the event as an opportunity for management to discuss pipeline updates and long-term strategy. Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
• Neutral Sentiment: Recent commentary suggests VRTX has been trading modestly above its last earnings level, with analysts debating whether the stock can keep advancing after its latest results. This is more of a valuation/expectations check than a direct catalyst. Vertex (VRTX) Up 0.2% Since Last Earnings Report: Can It Continue?
• Neutral Sentiment: Other articles highlighted that Vertex has recently underperformed the broader healthcare sector and that its shares have consolidated after a strong multi-year run. These pieces reflect investor debate around current valuation rather than a specific fundamental setback. Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

Insider Activity

In other news, EVP Joy Liu sold 1,104 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $425.02, for a total value of $469,222.08. Following the completion of the transaction, the executive vice president owned 20,729 shares in the company, valued at $8,810,239.58. This trade represents a 5.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 318 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $423.73, for a total value of $134,746.14. Following the completion of the transaction, the director owned 4,924 shares of the company’s stock, valued at approximately $2,086,446.52. The trade was a 6.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 11,717 shares of company stock worth $5,309,945 in the last quarter. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.